Sanuwave Health (NASDAQ:SNWV) Earns Buy Rating from Analysts at Roth Capital

Key Points

• Roth Capital initiated coverage on Sanuwave Health (NASDAQ:SNWV) with a "buy" rating and a price target of $49.00, indicating a potential upside of 37.06% from its current price.
• In contrast, Wall Street Zen downgraded the stock from a "buy" to a "hold" rating following Sanuwave's last quarterly earnings report showing a loss of ($0.66) EPS.
• Insider trading activity included significant stock sales by company executives, which reduced their ownership stakes, highlighting potential concerns regarding insider confidence in the company's future.

Analysts at Roth Capital initiated coverage on shares of Sanuwave Health (NASDAQ:SNWV - Get Free Report) in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The brokerage set a "buy" rating and a $49.00 price target on the stock. Roth Capital's target price indicates a potential upside of 35.21% from the stock's current price. Roth Capital also issued estimates for Sanuwave Health's Q2 2025 earnings at ($0.09) EPS, Q3 2025 earnings at $0.11 EPS, Q4 2025 earnings at $0.27 EPS, FY2025 earnings at ($0.36) EPS, Q1 2026 earnings at $0.07 EPS, Q2 2026 earnings at $0.15 EPS, Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.36 EPS, FY2026 earnings at $0.84 EPS and FY2027 earnings at $1.72 EPS.

Separately, Wall Street Zen cut Sanuwave Health from a "buy" rating to a "hold" rating in a research note on Saturday, May 24th.

Sanuwave Health Price Performance

SNWV stock traded down $2.23 during midday trading on Tuesday, hitting $36.24. 49,625 shares of the company's stock were exchanged, compared to its average volume of 54,710. The company's 50-day simple moving average is $32.68. The stock has a market capitalization of $310.54 million, a PE ratio of -7.95 and a beta of 1.24. Sanuwave Health has a 1-year low of $5.21 and a 1-year high of $39.83.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported ($0.66) earnings per share (EPS) for the quarter. The business had revenue of $9.34 million during the quarter.

Insider Buying and Selling at Sanuwave Health

In other news, COO Peter Stegagno sold 1,862 shares of the firm's stock in a transaction on Thursday, June 5th. The stock was sold at an average price of $27.71, for a total transaction of $51,596.02. Following the completion of the transaction, the chief operating officer directly owned 2,032 shares in the company, valued at $56,306.72. This trade represents a 47.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Iulian Cioanta sold 3,639 shares of the firm's stock in a transaction on Thursday, May 15th. The stock was sold at an average price of $31.60, for a total value of $114,992.40. Following the transaction, the insider owned 41 shares of the company's stock, valued at approximately $1,295.60. This represents a 98.89% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 14.90% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of SNWV. Strategic Investment Solutions Inc. IL purchased a new position in shares of Sanuwave Health during the first quarter worth $47,000. Goldman Sachs Group Inc. purchased a new position in Sanuwave Health in the first quarter valued at $337,000. Evernest Financial Advisors LLC purchased a new position in Sanuwave Health in the second quarter valued at $823,000. AWM Investment Company Inc. purchased a new position in Sanuwave Health in the first quarter valued at $18,153,000. Finally, Solas Capital Management LLC purchased a new position in Sanuwave Health in the first quarter valued at $20,658,000. 42.53% of the stock is currently owned by hedge funds and other institutional investors.

Sanuwave Health Company Profile

SANUWAVE Health, Inc, a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures.